Overview

Sermorelin is suggested to be a growth hormone analog constituting the first 29 amino acids out of the usual 44 amino acids found in growth hormone-releasing hormone (GHRH). Researchers posit that Sermorelin binds with the GHRH receptors found on the pituitary gland and suggest further that the synthetic peptide may stimulate secretion of growth hormone (hGH). Thus, Sermorelin is believed to maintain the fundamental function of GHRH, possibly stimulating the GHRH receptors in the pituitary gland and leading to sporadic release of growth hormone despite its reduced amino acid sequence. This mechanism is thought to result in increased levels of insulin-like growth factor-1 (IGF-1), primarily recognized for its role in the anabolic actions of growth hormone. The estimated half-life of Sermorelin is around 11 to 12 minutes.

A major potential advantage of the peptide is that due to its apparent GHRH receptor specificity, it may not induce any significant change in the levels of other endocrine markers such as prolactin, insulin, cortisol, glucose, or thyroid hormones.⁽⁶⁾